Akèy › Kansè vejik
Etid klinik pou Kansè vejik ap rekrite nan Etazini
141 etid pou Kansè vejik ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- New York City, NY34 etid
- Nashville, TN31 etid
- Houston, TX31 etid
- Dallas, TX27 etid
- Washington, DC26 etid
- Boston, MA26 etid
- Los Angeles, CA24 etid
- Baltimore, MD24 etid
- St. Louis, MO22 etid
- Edison, NJ22 etid
- Philadelphia, PA21 etid
- Chicago, IL21 etid
- Seattle, WA21 etid
- Durham, NC20 etid
- Cleveland, OH18 etid
- Columbus, OH18 etid
- Queens, NY16 etid
- Atlanta, GA15 etid
- Baldwin Park, CA14 etid
- San Antonio, TX13 etid
- Portland, OR13 etid
- Grand Rapids, MI12 etid
- Rochester, MN12 etid
- San Francisco, CA12 etid
- Kansas City, KS12 etid
- Austin, TX12 etid
- Orange, CA12 etid
- Staten Island, NY11 etid
- New Rochelle, NY11 etid
- Detroit, MI11 etid
- Birmingham, AL11 etid
- San Diego, CA11 etid
- Irvine, CA11 etid
- Minneapolis, MN11 etid
- Milwaukee, WI11 etid
- Denver, CO11 etid
- Oklahoma City, OK11 etid
- Greenburgh, NY10 etid
- East Norwalk, CT10 etid
- Salt Lake City, UT10 etid
Pa eta
- Alabama11 etid
- Alaska3 etid
- Arizona20 etid
- Arkansas15 etid
- Colorado20 etid
- Connecticut10 etid
- Delaware4 etid
- Distrik Columbia17 etid
- Florid38 etid
- Georgia18 etid
- Idaho6 etid
- Illinois30 etid
- Indiana14 etid
- Iowa12 etid
- Kalifòni53 etid
- Kansas17 etid
- Kentucky7 etid
- Lwizyàn13 etid
- Maryland36 etid
- Massachusetts31 etid
- Michigan25 etid
- Minnesota24 etid
- Mississippi3 etid
- Missouri27 etid
- Montana7 etid
- Nebraska11 etid
- Nevada4 etid
- New Hampshire3 etid
- New Jersey26 etid
- New Mexico3 etid
- New York40 etid
- North Carolina26 etid
- North Dakota4 etid
- Ohio36 etid
- Oklahoma12 etid
- Oregon14 etid
- Pennsylvania27 etid
- Rhode Island4 etid
- South Carolina16 etid
- South Dakota4 etid
- Tennessee34 etid
- Texas51 etid
- Utah14 etid
- Vermont3 etid
- Virginia24 etid
- Washington25 etid
- West Virginia5 etid
- Wisconsin17 etid
- Wyoming3 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 2 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT00026884Patient-Centered Surgical Prehabilitation
Ap rekriteVolontè an sante akeyi
Laj 18 a 85 · Tout sèks · Mizajou Sep 30, 2026 · NCT05715684The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07285044Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07061964Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder Cancer
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06394570Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06770582Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07566156Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07667335Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT03866382DK222 Study at Hopkins
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07140315A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06833073A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07206225Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07421700En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Sep 28, 2026 · NCT04235764A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07277413DESTINY-PANTUMOUR04
Ap rekriteEtid obsèvasyon
Laj 18 a 130 · Tout sèks · Mizajou Sep 25, 2026 · NCT07124000A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07419295A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06172478Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Ap rekriteFaz 1/2
Laj 18 a 99 · Tout sèks · Mizajou Sep 22, 2026 · NCT06814496A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07218380A Study of Surgical Techniques During Cystectomy
Ap rekriteFaz 3
Laj 21 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06703476Prehabilitation in High-risk Oncologic Surgery
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT07638410Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT06529822Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT05267626A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT06733363Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.